Correlation of antisynthetase antibody levels with disease course in a patient with interstitial lung disease and elevated muscle enzymes: Quantitation of antiglycyl tRNA synthetase antibodies by immunoprecipitation

Journal of Clinical Rheumatology

Volumn 2, Issue 2, 1996, Pages 89-94

  Stojanov, Lovorka ^a   Satoh, Minoru ^a   Hirakata, Michito ^b   Reeves, Westley H ^a,c  

^a UNIVERSITY OF NORTH CAROLINA   (United States)

^b KEIO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^c UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

Author keywords

Antiglycyl tRNA synthetase antibodies; Disease activity; Interstitial lung disease; Polymyositis; Quantitative immunoprecipitation; Systemic lupus erythematosus

Indexed keywords

AUTOANTIBODY; CREATINE KINASE; ENZYME ANTIBODY; GLYCINE TRANSFER RNA LIGASE;

ADULT; ANTIBODY BLOOD LEVEL; ANTIBODY DETECTION; ARTICLE; CASE REPORT; CLINICAL FEATURE; CREATINE KINASE BLOOD LEVEL; DISEASE COURSE; FEMALE; HUMAN; INTERSTITIAL LUNG DISEASE; POLYMYOSITIS; PRIORITY JOURNAL; SYSTEMIC LUPUS ERYTHEMATOSUS;

EID: 0029950939     PISSN: 10761608     EISSN: None     Source Type: Journal    
DOI: 10.1097/00124743-199604000-00006     Document Type: Article

References (24)

1. Mathews MB, Bernstein RM. Myositis autoantibody inhibits histidyl-tRNA synthetase: a model for autoimmunity. Nature 1983;304: 177-179.
2. Mathews MB, Reichlin M, Hughes GR, Bernstein RM. Anti-threonyl-tRNA synthetase, a second myositis-related autoantibody. J Exp Med 1984;160:420-434.
3. Targoff IN. Autoantibodies to aminoacyl-transfer RNA synthetases for isoleucine and glycine: two additional synthetases are antigenic in myositis. J Immunol 1990;144: 1737-1743.
4. Targoff IN, Trieu EP, Miller FW. Reaction of anti-OJ autoantibodies with components of the multi-enzyme complex of aminoacyl-tRNA synthetases in addition to isoleucyl-tRNA synthetase. J Clin Invest 1993;91:2556-2564.
5. Targoff IN. Humoral immunity in polymyositis/dermatomyositis. J Clin Dermatol 1993; (suppl)100:116-123.
6. Love LA, Leff RL, Fraser DD, et al. A new approach to the classification of idiopathic inflammatory myopathy: myositis-specific autoantibodies define a useful homogeneous patient group. Medicine (Baltimore) 1991;70: 360-374.
7. Miller BV, Waite KA, Biswas T, Plotz PH. The role of an autoantigen, histidyl-tRNA synthetase, in the induction and maintenance of autoimmunity. Proc Natl Acad Sci USA 1990;87: 9933-9937.
8. Miller FW, Twitty SA, Biswas T, Plotz PH. Origin and regulation of a disease-specific autoantibody response. Antigenic epitopes, spectrotype stability, and isotype restriction of anti-Jo-1 autoantibodies. J Clin Invest 1990;85: 468-475.
9. Targoff IN, Trieu EP, Plotz PH, Miller FW. Antibodies to glycyl-transfer RNA synthetase in patients with myositis and interstitial lung disease. Arthritis Rheum 1992;35:821-830.
10. Hirakata M, Mimori T, Akizuki M, Craft J, Hardin JA, Homma M. Autoantibodies to small nuclear and cytoplasmic ribonucleoproteins in Japanese patients with inflammatory muscle disease. Arthritis Rheum 1992;35:449-456.
11. Targoff IN. Autoantibodies in polymyositis. Rheum Dis Clin North Am 1992;18:455-482.
12. Satoh M, Ajmani AK, Ogasawara T, et al. Autoantibodies to RNA polymerase II are common in systemic lupus erythematosus and overlap syndrome. Specific recognition of the phosphorylated (IIO) form by a subset of human sera. J Clin Invest 1994;94:1981-1989.
13. Weinstein A, Bordwell B, Stone B, Tibbetts C, Rothfield NF. Antibodies to native DNA and serum complement (C3) levels: application to diagnosis and classification of systemic lupus erythematosus. Am J Med 1983;74:206-216.
14. Edworthy SM, Zatarain E, McShane DJ, Bloch DA. Analysis of the 1982 ARA lupus criteria data set by recursive partitioning methodology: new insights into the relative merit of individual criteria. J Rheumatol 1988;15:1493-1498.
15. Joffe MM, Love LA, Fraser DD, Hicks JE, Plotz PH, Miller FW. Drug therapy of the idiopathic inflammatory myopathies: predictors of response to prednisone, azathioprine, and methotrexate and a comparison of their efficacy. Am J Med 1993;94:379-386.
16. Targoff IN, Arnett FC. Clinical manifestations in patients with antibody to PL-12 antigen (alanyl-tRNA synthetase). Am J Med 1990;88:241-251.
17. Wasicek CA, Reichlin M, Montes M, Raghu G. Polymyositis and interstitial lung disease in a patient with anti-Jo-1 prototype. Am J Med 1984;76:538-544.
18. Friedman AW, Targoff IN, Arnett FC. Association of antibodies to aminoacyl-tRNA synthetases with lung disease without myositis (abstract). Arthritis Rheum 1994;37:S242.
19. Hirakata M, Nakamura K, Okano Y, et al. Anti-alanyl tRNA synthetase (PL-12) antibodies are associated with interstitial lung diseases in Japanese patients (abstract). Arthritis Rheum 1995; 38:S321.
20. Tan EM, Schur PH, Carr RI, Kunkel HG. Deoxyribonucleic acid (DNA) and antibodies to DNA in the serum of patients with systemic lupus erythematosus. J Clin Invest 1966;45: 1732-1740.
21. Emlen W, Pisetsky DS, Taylor RP. Antibodies to DNA. A perspective. Arthritis Rheum 1986; 29:1417-1426.
22. Bonfa E, Golombek SJ, Kaufman LD, et al. Association between lupus psychosis and anti-ribosomal P protein antibodies. N Engl J Med 1987;317:265-271.
23. Satoh M, Miyazaki K, Mimori T, et al. Changing autoantibody profiles with variable clinical manifestations in a patient with relapsing systemic lupus erythematosus and polymyositis. Br J Rheumatol 1995;34:915-919.
24. Fafalak RG, Peterson MGE, Kagan LJ. Strength in polymyositis and dermatomyositis: best outcome in patients treated early. J Rheumatol 1994;21:643-648.